CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, Dec. 15
Event: The JMP Securities Hematology Summit
The presentation will be webcast live and available for replay from the Investors section of
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in
CTI BioPharma Investor Contacts:
View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology-summit-on-tuesday-dec-15-301187816.html